Study guide
3.3 Diagnostic Imaging, ECG, and Device Interrogation
AAHFN Certified Heart Failure Nurse CHFN
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Patient History, Risk Factors, and Etiologies
1.1 Heart Failure Etiologies, Risk Factors, and Comorbid Conditions 1.2 Clinical History Taking, Social Determinants of Health, and Device History 1.3 Recognizing Signs and Symptoms of Heart Failure Decompensation
2 Chapter 2: Physical Examination and Hemodynamic Evaluation
2.1 Physical Assessment of Volume and Congestion Status 2.2 Physical Assessment of Perfusion and Low-Output States 2.3 Hemodynamic Profiling and Invasive Hemodynamics
3 Chapter 3: Laboratory Biomarkers and Diagnostic Testing
3.1 Natriuretic Peptides: BNP and NT-proBNP in Clinical Practice 3.2 Essential Laboratory Panels: Renal, Electrolyte, Hepatic, and Iron Evaluation 3.3 Diagnostic Imaging, ECG, and Device Interrogation
4 Chapter 4: Classification, Staging, and Functional Assessment
4.1 ACC/AHA Stages and LVEF Phenotypes 4.2 NYHA Functional Classification, 6-Minute Walk, and Quality-of-Life Measures 4.3 Frailty, Orthostatic Hypotension, and Age-Friendly Care Frameworks
5 Chapter 5: Individualized Care Planning and Shared Decision-Making
5.1 Care Setting Determination and Acuity Stratification 5.2 Formulating Etiology-Directed and Comorbidity-Integrated Goals 5.3 Shared Decision-Making, Patient Preferences, and Social Determinants
6 Chapter 6: GDMT Pharmacotherapy for HFrEF
6.1 The Four Pillars of GDMT: ARNI/ACEi/ARB, Beta-Blockers, MRA, and SGLT2i 6.2 Second-Line and Specialized Pharmacotherapy: Ivabradine, Vericiguat, Digoxin, and Hydralazine-Nitrates 6.3 Medications to Avoid and Drug Safety in Heart Failure
7 Chapter 7: Diuretics, HFpEF, Comorbidity Pharmacotherapy, and Medication Safety
7.1 Diuretic Strategies: Loop Diuretics, Conversions, and Sequential Nephron Blockade 7.2 Management of Heart Failure with Preserved (HFpEF), Mildly Reduced (HFmrEF), and Improved Ejection Fraction (HFimpEF) 7.3 Comorbidity-Directed Pharmacotherapy: Iron Repletion, Anticoagulation, and Immunizations 7.4 Medication Reconciliation, Adjunct Agents, and Drug-Level Monitoring
8 Chapter 8: Device Therapy, Rhythm Management, and Advanced Interventions
8.1 Implantable Devices: ICD and CRT Indications, Titration, and Screening 8.2 Advanced Heart Failure Therapies: Inotropes, Mechanical Circulatory Support (LVAD), and Heart Transplantation 8.3 Ambulatory Hemodynamic Monitoring and Ultrafiltration
9 Chapter 9: Patient Education, Self-Care, Screening, and Referrals
9.1 Self-Care Education and Daily Weight Monitoring 9.2 Dietary Sodium, Fluid Management, and Lifestyle Modifications 9.3 Exercise Prescription, Cardiac Rehabilitation, and Health Literacy 9.4 Individualized Teaching Plans and Learning Methods 9.5 Comorbidity Screening, Stress Management, and Referral Pathways
10 Chapter 10: Therapy Effectiveness, Monitoring, and Care Transitions
10.1 Monitoring and Titration Evaluation: GDMT Tolerance, Lab Trends, and Hemodynamics 10.2 Outpatient and Remote Monitoring Systems 10.3 Post-Acute Care Transitions and Preventing 30-Day Readmissions
11 Chapter 11: Patient Comprehension, Self-Care Adherence, and Palliative Transitions
11.1 Evaluating Patient and Caregiver Education Comprehension 11.2 Identifying and Addressing Adherence Barriers 11.3 Palliative Care, Goals of Care, and End-of-Life Device Management
12 Chapter 12: Professional Standards, Ethics, Quality, and Certification
12.1 Legal Parameters, Ethical Principles, and Patient Advocacy 12.2 Interdisciplinary Collaboration, SBAR Communication, and Care Coordination 12.3 Evidence-Based Guidelines, Quality Improvement, and Addressing Disparities 12.4 Certification, Continuing Education, and Professional Development
3.3 Diagnostic Imaging, ECG, and Device Interrogation
Key Takeaways Explain This Topic AI
Transthoracic echocardiography (TTE) using Simpson's biplane method is the primary imaging modality to determine LVEF, chamber geometry, and filling pressures, where an average E/e' ratio > 14 denotes elevated LV filling pressure.
Right ventricular systolic dysfunction is established by a tricuspid annular plane systolic excursion (TAPSE) < 17 mm, carrying profound adverse prognostic implications.
Chest radiography captures the hydrostatic congestion continuum: cephalization (PCWP 12–18 mmHg), interstitial edema with Kerley B lines (PCWP 18–25 mmHg), and alveolar bat-wing infiltrates (PCWP > 25 mmHg).
A 12-lead ECG demonstrating Left Bundle Branch Block (LBBB) morphology with QRS duration ≥ 150 ms provides a Class 1 indication for Cardiac Resynchronization Therapy (CRT).
Device interrogation mandates maintaining a biventricular pacing percentage > 98%, tracking thoracic impedance (OptiVol) alerts that precede overt failure by weeks, and monitoring CardioMEMS wireless pulmonary artery diastolic pressure trends (target 8–20 mmHg).
Last updated: September 2026
1. Transthoracic Echocardiography: Systolic Function, Remodeling, and Hemodynamics
Transthoracic Echocardiography (TTE) is the premier non-invasive diagnostic imaging modality in heart failure, mandatory for initial evaluation and clinical restaging.
Left Ventricular Ejection Fraction (LVEF) Assessment
The recommended standard for quantifying LVEF is the biplane Simpson's method of discs in apical 4-chamber and 2-chamber views. By contouring the endocardial border at end-diastole and end-systole, the method calculates end-diastolic volume (EDV) and end-systolic volume (ESV) without assuming geometric sphericity: LVEF = LVEDV − LVESV LVEDV × 100 % \text{LVEF} = \frac{\text{LVEDV} - \text{LVESV}}{\text{LVEDV}} \times 100\% LVEF = LVEDV LVEDV − LVESV × 100%
This defines the four core heart failure phenotypes:
- HFrEF (Heart Failure with Reduced EF): LVEF ≤ 40%
- HFmrEF (Heart Failure with Mildly Reduced EF): LVEF 41% to 49%
- HFpEF (Heart Failure with Preserved EF): LVEF ≥ 50%
HFimpEF (Heart Failure with Improved EF): Previous LVEF ≤ 40% with a follow-up measurement > 40% (the 2021 Universal Definition also requires a ≥ 10-point increase)
Other Ways LVEF Is Measured
The outline expects you to recognize ejection fraction reported from several tests:
Nuclear imaging: Gated SPECT or a MUGA (radionuclide ventriculography) scan gives a reproducible, count-based LVEF that is useful for serial monitoring, such as during cardiotoxic chemotherapy.
Cardiac MRI: The reference standard for volumes and LVEF; late gadolinium enhancement also shows scar, infiltration (amyloidosis, sarcoidosis), and myocarditis.
Cardiac CT: Can estimate LVEF from ECG-gated images while it evaluates coronary anatomy.
Left ventriculography during cardiac catheterization: Contrast injected into the left ventricle provides an LVEF estimate at the time of coronary angiography.
Values differ modestly between modalities, so trend LVEF with the same test when possible before relabeling a phenotype.
Ventricular Dimensions and Geometric Remodeling
Echocardiography distinguishes adaptive and maladaptive architectural remodeling by assessing left ventricular end-diastolic diameter (LVEDD), wall thickness, and relative wall thickness (RWT) : Relative Wall Thickness (RWT) = 2 × Posterior Wall Thickness (PWT) Left Ventricular End-Diastolic Diameter (LVEDD) \text{Relative Wall Thickness (RWT)} = \frac{2 \times \text{Posterior Wall Thickness (PWT)}}{\text{Left Ventricular End-Diastolic Diameter (LVEDD)}} Relative Wall Thickness (RWT) = Left Ventricular End-Diastolic Diameter (LVEDD) 2 × Posterior Wall Thickness (PWT)
Concentric Remodeling: Normal LV mass index with elevated RWT (> 0.42).
Concentric Hypertrophy: Increased LV mass index with elevated RWT (> 0.42); classic hallmark of chronic systemic hypertension and aortic stenosis.
Eccentric Hypertrophy: Increased LV mass index with normal or decreased RWT (≤ 0.42); characterized by chamber dilation out of proportion to wall thickness, typical of ischemic cardiomyopathy, mitral regurgitation, and dilated cardiomyopathy.
Right Ventricular (RV) Size and Systolic Performance
Because the thin-walled right ventricle is sensitive to afterload changes induced by left heart congestion, RV dysfunction is an independent predictor of cardiogenic shock and death. Key echocardiographic RV parameters include:
Tricuspid Annular Plane Systolic Excursion (TAPSE): M-mode measurement of the longitudinal excursion of the lateral tricuspid annulus toward the apex. TAPSE < 17 mm defines RV systolic dysfunction.
RV Tissue Doppler Systolic Velocity (S'): Peak systolic velocity of the lateral tricuspid annulus. S' < 9.5 cm/s indicates impaired RV contractility.
Fractional Area Change (FAC): Percentage change in RV area from diastole to systole. FAC < 35% denotes systolic failure.
Pulmonary Artery Systolic Pressure (PASP)
PASP is estimated non-invasively using continuous-wave Doppler interrogation of the tricuspid regurgitant (TR) jet velocity and applying the modified Bernoulli equation : PASP = 4 × ( V TR ) 2 + Estimated Right Atrial Pressure (RAP) \text{PASP} = 4 \times (V_{\text{TR}})^2 + \text{Estimated Right Atrial Pressure (RAP)} PASP = 4 × ( V TR ) 2 + Estimated Right Atrial Pressure (RAP)
Right atrial pressure is derived from the inferior vena cava (IVC) diameter and its percentage collapse during normal inspiration:
IVC ≤ 2.1 cm with > 50% inspiratory collapse: Normal RAP (~3 mmHg).
IVC > 2.1 cm with < 50% inspiratory collapse: Severely elevated RAP (~15 mmHg).
Intermediate scenarios: RAP ~8 mmHg.
2. Diastolic Function and Intracardiac Filling Pressures
Elevated left ventricular filling pressure is the common physiological endpoint of symptomatic heart failure regardless of LVEF. DIASTOLIC PRESSURE INTERROGATION:
1. Mitral Inflow Insonation (Pulsed-Wave Doppler at Leaflet Tips):
- E Wave = Early rapid diastolic filling velocity
- A Wave = Late diastolic filling velocity from atrial contraction
- E/A Ratio normal: 0.8 to 1.5; Restrictive (Elevated LAP): > 2.0
2. Tissue Doppler Imaging (TDI at Mitral Annulus):
- e' Velocity = Early diastolic annular tissue relaxation speed
- Septal e' < 7 cm/s or Lateral e' < 10 cm/s indicates impaired myocyte relaxation
3. The E/e' Ratio (Hemodynamic Surrogate for PCWP):
- E / e' Ratio < 8 --> Normal LV Filling Pressures (PCWP < 12 mmHg)
- E / e' Ratio 8-14 --> Indeterminate / Gray Zone
- E / e' Ratio > 14 --> ELEVATED LV FILLING PRESSURES (PCWP > 15 mmHg)
4. Structural Correlates of Chronic Diastolic Stress:
- Left Atrial Volume Index (LAVI) > 34 mL/m²
- Peak Tricuspid Regurgitant Velocity > 2.8 m/s
- 3. Chest Radiography: The Hydrostatic Congestion Continuum
In acute decompensation, chest radiography (CXR) visualizes the anatomical progression of hydrostatic pulmonary congestion driven by rising pulmonary capillary wedge pressure (PCWP).
Radiographic Finding Description Hemodynamic Correlation
Cardiomegaly Cardiothoracic ratio (CTR) > 0.50 on PA projection (cardiac silhouette exceeds 50% of maximal thoracic width). May be absent in acute first-time infarction. Chronic ventricular dilation / volume overload
Stage 1: Cephalization ("Stag's Antler") Dilation and redistribution of pulmonary blood flow to upper lobes (apical vessels caliber ≥ lower lobe vessels at the same distance from hilum). PCWP 12–18 mmHg (early pulmonary venous hypertension)
Stage 2: Interstitial Edema (Kerley B Lines) Transudation of fluid into interlobular septa and peribronchial spaces. Manifests as Kerley B lines : short (1–2 cm), thin horizontal linear densities perpendicular to the pleura at the lung bases, accompanied by perihilar haziness and peribronchial cuffing. PCWP 18–25 mmHg (lymphatic drainage capacity exceeded)
Stage 3: Alveolar Edema ("Bat-Wing" / "Butterfly") Intra-alveolar fluid transudation producing dense, bilateral, fluffy, symmetric perihilar infiltrates sparing the cortical lung periphery. PCWP > 25 mmHg (overt alveolar flooding)
Pleural Effusions Blunting of lateral and posterior costophrenic angles (meniscus sign). Typically transudative and asymmetric (Right > Left) due to larger right pleural surface area and venous anatomy. Sustained systemic and pulmonary venous hypertension
4. 12-Lead Electrocardiography: Conduction, Ischemia, and Dyssynchrony
Every heart failure patient requires a baseline 12-lead ECG, repeated with each change in clinical status.
QRS Duration and Conduction Abnormalities
Normal ventricular depolarization occurs in < 120 ms. Prolongation of the QRS complex (≥ 120 ms) reflects intraventricular conduction delay and abnormal electrical activation, causing mechanical dyssynchrony between the interventricular septum and LV free wall.
Left Bundle Branch Block (LBBB) and CRT Response
ECG Criteria for LBBB:
QRS duration ≥ 120 ms (complete bundle branch block).
Broad, notched or slurred R waves in lateral leads (I, aVL, V₅, V₆) with absence of Q waves.
Wide, deep rS or QS complexes in right precordial leads (V₁, V₂).
ST-T wave vector discordant with the primary QRS deflection.
Predicting Cardiac Resynchronization Therapy (CRT) Benefit: Large randomized clinical trials (MADIT-CRT, RAFT, COMPANION) established that the magnitude of CRT benefit correlates directly with QRS morphology and width:
Class 1 Indication: Patients with LBBB morphology and QRS duration ≥ 150 ms in sinus rhythm with LVEF ≤ 35% and NYHA class II, III, or ambulatory class IV symptoms on optimal GDMT experience the most dramatic reverse remodeling, symptom reduction, and survival extension.
Class 2a/2b: Non-LBBB morphology (e.g., Right Bundle Branch Block or nonspecific IVCD) or QRS between 120 and 149 ms derive significantly less benefit.
Ischemic and Hypertrophic Patterns
Pathologic Q Waves: Width ≥ 0.04 seconds (1 small box) and depth > 25% of following R wave amplitude in ≥ 2 contiguous leads, indicating prior transmural infarction and myocardial scar.
Left Ventricular Hypertrophy (LVH): Evaluated via the Sokolow-Lyon index (S(V1) + R(V5/V6) ≥ 35 mm) or Cornell voltage criteria (R(aVL) + S(V3) > 28 mm in men, > 20 mm in women).
Arrhythmias: Atrial fibrillation (loss of organized P waves with irregularly irregular ventricular response) triggers acute decompensation by abolishing atrial contribution to ventricular filling ("atrial kick," which provides 20–30% of cardiac output in stiff ventricles) and inducing tachycardia-mediated cardiomyopathy.
Cardiac Catheterization: Left and Right Heart
Left heart catheterization with coronary angiography identifies obstructive coronary artery disease as the cause of new cardiomyopathy and guides revascularization decisions by the heart team. It also measures left ventricular end-diastolic pressure (LVEDP).
Right heart catheterization measures right atrial, pulmonary artery, and wedge pressures, cardiac output, and pulmonary vascular resistance (see section 2.3). It is used when volume or perfusion status is unclear, for cardiogenic shock, and in advanced therapy or transplant evaluation.
Nursing priorities after catheterization: Check the access site and distal pulses, watch for bleeding or hematoma, monitor renal function after contrast, and review whether diuretics or metformin were held.
5. Cardiac Device Interrogation and Ambulatory Sensor Monitoring
Remote monitoring and device interrogation provide objective, continuous physiological data that precede clinical symptoms.
Remote Monitoring and Biventricular Pacing Percentage
For patients with CRT pacemakers (CRT-P) or CRT defibrillators (CRT-D), maintaining a high biventricular (BiV) pacing percentage is mandatory: BiV Pacing Target > 98 % ( Ideally > 99 % ) \text{BiV Pacing Target} > 98\% \quad (\text{Ideally } > 99\%) BiV Pacing Target > 98% ( Ideally > 99% )
Outcomes worsen progressively as the percentage falls below about 98%. Common culprits for lost BiV pacing include:
Atrial fibrillation with rapid ventricular response (native conduction outpaces the paced ventricular cycle).
Frequent premature ventricular contractions (PVCs) interrupting scheduled BiV pacing.
Suboptimal programmed atrioventricular (AV) or interventricular (VV) delay intervals.
Lead dislodgement, diaphragmatic stimulation, or elevated pacing thresholds leading to loss of capture.
Nursing Intervention: When BiV pacing falls below 98%, the priority is evaluating for atrial arrhythmias, optimizing AV nodal blocking agents (beta-blockers, digoxin), considering catheter ablation of the AV node, or reprogramming pacing parameters.
Thoracic Impedance (The OptiVol Fluid Index)
Implantable devices measure electrical impedance across the lead in the right ventricle to the pulse generator in the pectoral pocket. Electrical current travels more easily through fluid than through aerated lung tissue: Pulmonary Interstitial Fluid Accumulation ⟹ Decreased Intrathoracic Electrical Impedance \text{Pulmonary Interstitial Fluid Accumulation} \implies \text{Decreased Intrathoracic Electrical Impedance} Pulmonary Interstitial Fluid Accumulation ⟹ Decreased Intrathoracic Electrical Impedance
When daily impedance drops below the patient's moving baseline, the device accumulates the difference into a fluid index (e.g., OptiVol 2.0 ). When this index crosses a programmable threshold (typically 60 to 80 Ω-days ), an alert is triggered. Importantly, thoracic impedance alerts precede overt clinical weight gain and shortness of breath by 10 to 21 days , providing an early window for outpatient diuretic adjustment.
Ventricular Tachyarrhythmia Burden
Interrogation quantifies episodes of non-sustained ventricular tachycardia (NSVT), sustained VT, and ventricular fibrillation (VF), as well as delivered therapies ( anti-tachycardia pacing [ATP] and high-energy defibrillation shocks). Frequent shocks ("ICD storm") or clustering NSVT indicates worsening myocardial ischemia, electrolyte derangements (hypokalemia, hypomagnesemia), or worsening hemodynamic decompensation.
Loop Recorders and Wearable Cardioverter-Defibrillators
Implantable loop recorder (ILR): A small subcutaneous monitor that records rhythm for about 3 years. Reports flag atrial fibrillation burden, pauses, and ventricular arrhythmias. It cannot pace or shock, so a recorded pause or VT needs prompt review.
Wearable cardioverter-defibrillator (WCD): A vest worn during a temporary high-risk period, such as the waiting time before an ICD decision. Downloads show wear time (daily use under about 20 hours limits protection), detected arrhythmias, and any shocks. Nurses reinforce continuous wear and explain the alarms and response buttons.
Wireless Pulmonary Artery Pressure Monitoring (CardioMEMS)
The CardioMEMS sensor is a miniaturized, battery-free, wireless radiofrequency sensor permanently deployed in a distal branch of the descending pulmonary artery via right heart catheterization. The patient takes daily transmissions from home using a sensor-embedded pillow.
Clinical Parameter: Measures real-time pulmonary artery systolic, mean, and pulmonary artery diastolic pressure (PADP) .
Physiological Basis: PADP closely approximates left atrial pressure and pulmonary capillary wedge pressure (a commonly used individualized target range: 8 to 20 mmHg ).
Decompensation Timeline: PADP rises 2 to 4 weeks prior to any change in daily patient weight or clinical symptoms. In the landmark CHAMPION trial, proactive, clinician-directed titration of diuretics and vasodilators guided by daily CardioMEMS transmissions reduced heart failure hospitalizations by 37% compared to standard symptom-guided management.
- 6. Clinical Application Scenario, Diagnostic Traps, and Board Review
- Clinical Case Scenario
A 66-year-old male with non-ischemic cardiomyopathy, LVEF 25%, and a CRT-D placed 18 months ago presents to the outpatient clinic with mild exertional dyspnea. Device interrogation reveals: Biventricular pacing percentage has fallen from 99.2% to 84.1%; OptiVol fluid index is 78 Ω-days (threshold 60 Ω-days); and the device log displays 4,200 episodes of atrial tachycardia/atrial fibrillation over the past 3 weeks with a mean ventricular rate of 118 bpm.
Action Plan: The drop in BiV pacing to 84.1% is directly caused by rapid atrial fibrillation competing with and inhibiting device pacing. The elevated OptiVol index indicates subclinical pulmonary fluid accumulation. The nurse promptly coordinates medication adjustment: uptitrating beta-blocker therapy to achieve resting heart rate < 80 bpm (or initiating digoxin), temporarily increasing oral loop diuretic for 5 days, and scheduling an electrophysiology review for potential AF rhythm control or AV junction ablation. Within two weeks, resting heart rate is controlled at 72 bpm, BiV pacing recovers to 99.4%, and OptiVol normalizes without hospitalization.
CHFN Diagnostic Pearls and Exam Traps
The E/e' Ratio Cutoff: Remember that E/e' > 14 reliably indicates elevated LV filling pressures (PCWP > 15 mmHg). An E/e' < 8 indicates normal filling pressures.
The TAPSE Threshold: A TAPSE < 17 mm indicates right ventricular failure. Do not confuse it with left ventricular parameters.
The CRT Response Predictor: The highest-yield candidate for CRT is LBBB with QRS ≥ 150 ms in sinus rhythm. Non-LBBB morphology is far less responsive.
The 98% BiV Pacing Imperative: Any question citing biventricular pacing below 98% indicates suboptimal therapy requiring aggressive rate control or device reprogramming.
The Early Warning Sequence: Pulmonary artery pressures (CardioMEMS) and thoracic impedance (OptiVol) rise 2–3 weeks before weight gain and overt dyspnea occur. Daily weights alone catch decompensation late!